Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 6/20 | 0.80 |
| ▸ | GRPR | P30550 | 1/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | ITGAL | P20701 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FPR1 | P21462 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809992 | 0.84 | NMBR (1.00) | NMBRGRPRBCHEITGB2ICAM1 | |
| SCHEMBL7671985 | 0.79 | NMBR (0.65) | NMBRGRPRBCHEITGB2ICAM1 | |
| SCHEMBL6181433 | 0.76 | NMBR (1.00) | NMBRGRPRBCHEITGB2ICAM1 | |
| SCHEMBL6181017 | 0.76 | NMBR (1.00) | NMBRGRPRBCHEITGB2ICAM1 | |
| SCHEMBL14571110 | 0.76 | NMBR (0.71) | NMBRMAPT | |
| SCHEMBL8574758 | 0.75 | NMBR (0.75) | NMBRGRPRBCHE | |
| SCHEMBL6020862 | 0.72 | CTSL (0.67) | NMBRBCHEITGB2ICAM1ITGAL | |
| SCHEMBL3849151 | 0.72 | ITGB2 (0.61) | NMBRBCHEITGB2ICAM1ITGAL | |
| SCHEMBL3848227 | 0.72 | ITGB2 (0.61) | NMBRBCHEITGB2ICAM1ITGAL | |
| SCHEMBL3848230 | 0.72 | ITGB2 (0.61) | NMBRBCHEITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087561-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY LLC | 2004-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087561-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | NMBR 258/4885GRPR 199/4885BCHE 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.